Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB1 | P05556 | 12/20 | 0.35 |
| ▸ | ITGA4 | P13612 | 12/20 | 0.35 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.34 |
| ▸ | PPARG | P37231 | 4/20 | 0.33 |
| ▸ | PPARA | Q07869 | 1/20 | 0.32 |
| ▸ | PTGDR | Q13258 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5335132 | 0.92 | ELANE (0.34) | KDM4C | |
| SCHEMBL5262264 | 0.91 | ITGB1 (0.38) | ITGB1ITGA4PPARGPPARAMAPT | |
| SCHEMBL5260326 | 0.91 | ITGB1 (0.38) | ITGB1ITGA4PPARGPPARAMAPT | |
| SCHEMBL5313936 | 0.90 | EGLN1 (0.31) | PPARGPPARA | |
| SCHEMBL5260488 | 0.90 | ITGB1 (0.38) | ITGB1ITGA4KDM4CPPARG | |
| SCHEMBL5262062 | 0.87 | MME (0.33) | ITGB1ITGA4 | |
| SCHEMBL5259901 | 0.85 | ITGB1 (0.35) | ITGB1ITGA4 | |
| SCHEMBL5259895 | 0.85 | ITGB1 (0.35) | ITGB1ITGA4 | |
| SCHEMBL5264252 | 0.83 | PPARG (0.33) | ITGB1ITGA4PPARGPPARA | |
| SCHEMBL5262851 | 0.82 | NLRP3 (0.33) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1332132-B1 | ENAMINE DERIVATIVES AS CELL ADHESION MOLECULES | UCB PHARMA SA (BE) | 2007-10-10 | — | — | EP | claimed |
| US-20030229116-A1 | ENAMINE DERIVATIVES | UCB PHARMA S.A. (BE) | 2003-12-11 | — | — | US | claimed |
| US-6610700-B2 | Inhibit binding of integrins to their ligands, use in immune or inflammatory disorders; 3-(4-((2,6-Naphthyridinyl)amino)-phenyl)-2-((2-(1-ethylpropyl)-3-oxo-1 -cyclopentenyl) amino)-propionic acid, for example | CELLTECH R & D LIMITED (GB) | 2003-08-26 | — | — | US | claimed |
| EP-1332132-A2 | ENAMINE DERIVATIVES AS CELL ADHESION MOLECULES | Celltech R&D Limited (GB) | 2003-08-06 | — | — | EP | claimed |
| US-20020037909-A1 | Enamine derivatives | UCB PHARMA S.A. (BE) | 2002-03-28 | — | — | US | claimed |
| WO-2001079173-A2 | ENAMINE DERIVATIVES AS CELL ADHESION MOLECULES | CELLTECH R & D LIMITED (GB) | 2001-10-25 | — | — | WO | claimed |
| EP-1332132-B1 | ENAMINE DERIVATIVES AS CELL ADHESION MOLECULES | UCB PHARMA SA (BE) | 2007-10-10 | — | — | EP | disclosed |
| US-6780874-B2 | AUTOIMMUNE DISEASE; ANTIINFLAMMATORY AGENTS; ANTIPROLIFERATIVE AGENT | CELLTECH R & D LIMITED (GB) | 2004-08-24 | — | — | US | disclosed |
| US-20030229116-A1 | ENAMINE DERIVATIVES | UCB PHARMA S.A. (BE) | 2003-12-11 | — | — | US | disclosed |
| US-6610700-B2 | Inhibit binding of integrins to their ligands, use in immune or inflammatory disorders; 3-(4-((2,6-Naphthyridinyl)amino)-phenyl)-2-((2-(1-ethylpropyl)-3-oxo-1 -cyclopentenyl) amino)-propionic acid, for example | CELLTECH R & D LIMITED (GB) | 2003-08-26 | — | — | US | disclosed |
| EP-1332132-A2 | ENAMINE DERIVATIVES AS CELL ADHESION MOLECULES | Celltech R&D Limited (GB) | 2003-08-06 | — | — | EP | disclosed |
| US-20020037909-A1 | Enamine derivatives | UCB PHARMA S.A. (BE) | 2002-03-28 | — | — | US | disclosed |
| WO-2001079173-A2 | ENAMINE DERIVATIVES AS CELL ADHESION MOLECULES | CELLTECH R & D LIMITED (GB) | 2001-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020037909-A1 | Enamine derivatives | CCR1, ITGB2, CCR10 | ITGB1 4/4885ITGA4 72/4885KDM4C 4095/4885 |
| US-20030229116-A1 | ENAMINE DERIVATIVES | ITGB2, CCR1, CCR10 | ITGB1 4/4885ITGA4 67/4885KDM4C 4084/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.